ONGLYZA® (saxagliptin)

How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?

SAVOR: The Onglyza CV outcomes study

Cardiovascular risk: Baseline characteristics

Baseline vascular risk factors1

Baseline vascular risk factors
Baseline vascular risk factors

CV outcomes trials for other DPP-4 inhibitors are published but are not presented within this document.
If further information is required, please contact the respective pharmaceutical company.

The 16.492 highly comorbid patients on the SAVOR study had a history of documented T2D, an HbA1c level of 6.5-12.0% and either a history of established cardiovascular disease or multiple risk factors for vascular disease1

1. Scirica BM et al. N Engl J Med 2013; 369: 1317-1326.